The Stockholm Stock Exchange started the year with broad gains - OMXS30 +1.0 percent
At the close, the OMXS30 index was up 1.04 percent to 2,508.83. Shares worth around SEK 13.2 billion were traded on the Stockholm Stock Exchange.
The best performance among the stock exchange's major industrial sectors was energy with a rise of 6.6 percent. No sector went down.
Among the leading stocks, which are included in the OMXS30 index, Kinnevik rose 4.8 percent while Tele 2 was up 2.1 percent. Saab was the worst performer, down 0.4 percent, while ABB was down 0.4 percent.
Credit management company Intrum shot up 11.9 percent. A US bankruptcy court has approved the company's prepackaged Chapter 11 reorganization plan. This means that the motion to dismiss the Chapter 11 process filed by a minority group of bondholders has been rejected.
Pareto included Embracer and Hemnet in its Swedish model portfolio for January. The shares rose 10.6 percent and 5.5 percent respectively. They replace Volvo and Catena.
Boozt has released preliminary figures for the full year 2024. Christmas shopping was disappointing and full-year growth amounted to 6 percent, which was lower than the guidance of 7 percent growth. Net sales amounted to 8,215 million SEK for the full year. The expectation was 8,339 million, according to Bloomberg's compilation of analyst estimates. The adjusted operating margin was 5.2 percent, in line with the guidance of 5.2-5.4 percent. The stock fell 2.5 percent.
Technology company Image Systems reports new orders, this time an order for the RemaSawco business area worth SEK 7.2 million. The share was unchanged.
The research company Mendus has received positive feedback from the FDA and EMA regarding the plans for a pivotal phase 3 study with the company's main program vididencel for the treatment of acute myeloid leukemia (AML). The share increased 7.7 percent.
Biotechnology company Xbrane Biopharma has resubmitted a Biologics License Application (BLA) for its biosimilar candidate to Genentech's Lucentis (ranibizumab) to the US Food and Drug Administration (FDA). The stock rose 10.1%.
Go to the original article.
Contact us to request a correction